These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36987605)

  • 1. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.
    He J; Li Z
    Rheumatology (Oxford); 2023 Mar; 62(Suppl 1):i22-i29. PubMed ID: 36987605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Hu SC; Yen FL; Wang TN; Lin YC; Lin CL; Chen GS
    J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic lupus erythematosus and risk of infection.
    Barber MRW; Clarke AE
    Expert Rev Clin Immunol; 2020 May; 16(5):527-538. PubMed ID: 32478627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of immunosuppressants on the non-melanoma skin cancer among patients with systemic lupus erythematosus and primary Sjögren's syndrome: a nationwide retrospective case-control study in Taiwan.
    Tseng HW; Huang WC; Lu LY
    Clin Exp Rheumatol; 2019; 37(6):946-952. PubMed ID: 31074727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study.
    Bello N; Birt JA; Workman J; Zhou X; Ross-Terres JA; Petri M
    Adv Ther; 2022 Jul; 39(7):3131-3145. PubMed ID: 35534786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-central serous chorioretinopathy in a patient with systemic lupus erythematosus and hydroxychloroquine retinopathy.
    Hipolito-Fernandes D; Luís ME; Flores R; Anjos R
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33462009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment pathways in an inception lupus cohort over the first three years.
    Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
    Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious complications in SLE after immunosuppressive therapies.
    Kang I; Park SH
    Curr Opin Rheumatol; 2003 Sep; 15(5):528-34. PubMed ID: 12960476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
    Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
    Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Inoue Y; Ueno M; Tanaka Y
    Int J Rheum Dis; 2019 Mar; 22(3):434-442. PubMed ID: 30338639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 14. [Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems].
    Astudillo L; Sailler L; Carreiro M; Dahan S; Ollier S; Arlet P
    Ann Med Interne (Paris); 2003 Feb; 154(1):3-6. PubMed ID: 12746653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus.
    Kwon HH; Bang SY; Won S; Park Y; Yi JH; Joo YB; Lee HS; Bae SC
    Lupus; 2018 Sep; 27(10):1644-1651. PubMed ID: 29950160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
    Joo YB; Sung YK; Shim JS; Kim JH; Lee EK; Lee HS; Bae SC
    Rheumatol Int; 2015 May; 35(5):879-86. PubMed ID: 25300729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the Detection of Subclinical Retinal Involvement in Systemic Lupus Erythematosus and Sjögren Syndrome: A Potential Association with Therapies.
    Conigliaro P; Triggianese P; Draghessi G; Canofari C; Aloe G; Chimenti MS; Valeri C; Nucci C; Perricone R; Cesareo M
    Int Arch Allergy Immunol; 2018; 177(1):45-56. PubMed ID: 29902805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for juvenile-onset systemic lupus erythematosus.
    Carreño L; López-Longo FJ; González CM; Monteagudo I
    Paediatr Drugs; 2002; 4(4):241-56. PubMed ID: 11960513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
    Lee SG; Park EK; Park JH; Kweon SM; Kim YK; Kim GT
    Lupus; 2018 Apr; 27(5):753-761. PubMed ID: 29157178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infections in systemic lupus erythematosus.
    Navarra SV; Leynes MS
    Lupus; 2010 Oct; 19(12):1419-24. PubMed ID: 20947551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.